Assessing the acceptability of, adherence to and preference for a dual prevention pill (DPP) for HIV and pregnancy prevention compared to oral pre-exposure prophylaxis (PrEP) and oral contraception taken separately: protocols for two randomised, controlled, cross-over studies in South Africa and Zimbabwe
Barbara A Friedland,Nyaradzo M Mgodi,Thesla Palanee-Phillips,Sanyukta Mathur,Marlena G Plagianos,Irene V Bruce,Maud Lansiaux,Caroline Murombedzi,Petina Musara,Adlight Dandadzi,Krishnaveni Reddy,Nkosiphile Ndlovu,Sihle K Zulu,Lerato R Shale,Brady Zieman,Lisa B Haddad,Friedland,B. A.,Mgodi,N. M.,Palanee-Phillips,T.,Mathur,S.,Plagianos,M. G.,Bruce,I. V.,Lansiaux,M.,Murombedzi,C.,Musara,P.,Dandadzi,A.,Reddy,K.,Ndlovu,N.,Zulu,S. K.,Shale,L. R.,Zieman,B.,Haddad,L. B.
DOI: https://doi.org/10.1136/bmjopen-2023-075381
IF: 3.006
2024-03-13
BMJ Open
Abstract:Introduction Oral pre-exposure prophylaxis (PrEP) is a highly effective HIV prevention method; however, uptake and persistence have been low among southern African women. A dual prevention pill (DPP) that combines PrEP with oral contraception (OC) may increase PrEP use and better meet women's sexual and reproductive health needs. We will gauge the DPP's acceptability in two cross-over clinical trials. Methods and analysis PC952 (Zimbabwe) and PC953 (South Africa) will compare acceptability, adherence and preference for an over-encapsulated DPP versus PrEP and OCs taken separately. HIV-negative, non-pregnant cisgender females in Johannesburg, South Africa (n=96, 16–40 years) and Harare, Zimbabwe (n=30, 16–24 years) will be randomised 1:1 to the order of regimens—DPP or two separate tablets—each used for three 28-day cycles, followed by a 6-month choice period in South Africa. Monthly clinic visits include HIV and pregnancy testing; safety assessments and risk reduction and adherence counselling. We will assess adherence (monthly) based on tenofovir diphosphate drug levels in dried blood spots and by self-report. We will evaluate acceptability (monthly) and preference (end of cross-over) via computer-assisted self-interviewing and in-depth interviews with a subset of participants. Data collection started in September 2022 and ended in January 2024. Ethics and dissemination PC952 was approved by the Ministry of Health and Child Care, Medical Research Council, Research Council and Medicines Control Authority of Zimbabwe; the Chitungwiza City Health Ethics Committee; and the Joint Research Ethics Committee for the University of Zimbabwe Faculty of Medicine and Health Sciences and Parirenyatwa Group of Hospitals. PC953 was approved by the South African Health Products Regulatory Authority and the University of the Witwatersrand's Human Research Ethics Committee. The Population Council IRB approved both studies. We will disseminate results in open-access journals, clinical trials registries, and at local and international meetings and conferences. Trial registration numbers NCT04778514, NCT04778527.
medicine, general & internal